Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits, Vector & Virus, Western Blot
Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review
Amber
- posted on
- No Comment
Introduction: Multiple myeloma is a hematologic disease that is progressive and incurable characterized by irregular and clonal multiplication plasmacytes in the bone marrow. The main clinical manifestations caused by the presence of neoplastic cells in the bone tissue, and excessive production of immunoglobulins and humoral immune suppression normal. Daratumumab is an anti-CD38 monoclonal antibody that promise results in managing the disease multiple myeloma.
Objective: This study aimed to determine the scientific evidence regarding the impact of cytomegalovirus infection in treatment programs daratumumab in multiple myeloma patients extensively pre-treatment.
Methods: For this purpose, an integrative literature review conducted on a different database, which consists of a period of 5 years.
Results: The study analysis revealed that the reactivation of cytomegalovirus infection may occur during the use of daratumumab in previously treated multiple myeloma patients, which led to discontinuation of treatment, compromised drug efficacy and disease progression favored. In addition, it was observed that even with prophylactic antiviral therapy there is a reactivation of infection in some cases, and death, in a more serious situation.
Conclusion: So, even considering some of the reports on these topics is available in the scientific literature, this review suggests that cytomegalovirus reactivation can interfere daratumumab therapy, especially in heavily pretreated multiple myeloma patients. In addition, this research can contribute as a tool for clinical decisions and management of adverse events in medical practice, demonstrating the importance of monitoring patients for the possibility of cytomegalovirus reactivation in patients with heavily pretreated myeloma.
Comparison of different cytomegalovirus disease following haploidentical hematopoietic stem cell transplantation
Cytomegalovirus (CMV) can cause end-organ disease including pneumonia, gastroenteritis, retinitis, and encephalitis in hematopoietic stem cell transplant recipients. the potential difference between the different CMV disease remains uncertain.
This study aimed to compare the clinical characteristics, risk factors, and mortality among the different CMV disease. A retrospective case-control study carried out based on a cohort of 3862 patients undergoing haploidentical hematopoietic stem cell transplantation in a single-center. CMV disease occurred in 113 (2.92%) of 3,862 haplo-HSCT recipients, including the possibility of CMV pneumonia (CMVP, n = 34), proved to CMV gastroenteritis (CMVG, n = 34), CMV retinitis (CMVR, n = 31) , the possibility of CMV encephalitis (CMVE, n = 7), and disseminated CMV disease (Di-CMVD, n = 7). Most (91.2%) cases CMVG developed in 100 days, while the majority (90.3%) cases of late-onset CMVR.
 Lenti-hTERT virus |
|||
| G200 | ABM | 10 ml | EUR 811 |
 Lenti-Bmi1 Virus |
|||
| LV610 | ABM | 10 ml | EUR 811 |
 Lenti-CDK4 Virus |
|||
| LV611 | ABM | 10 ml | EUR 811 |
 Rev-A3R5-GFP/Luc HIV Reporter Cells |
|||
| HRC-2 | 101Bio | - | Ask for price |
 Rev-CEM-GFP/Luc HIV Reporter Cells |
|||
| HRC-5 | 101Bio | - | Ask for price |
 AAV2-Luc Control Virus |
|||
| AAV-320 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 2. |
|||
 AAV1-Luc Control Virus |
|||
| AAV-321 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 1. |
|||
 AAV3-Luc Control Virus |
|||
| AAV-323 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 3. |
|||
 AAV4-Luc Control Virus |
|||
| AAV-324 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 4. |
|||
 AAV5-Luc Control Virus |
|||
| AAV-325 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 5. |
|||
 AAV6-Luc Control Virus |
|||
| AAV-326 | Cell Biolabs | 50 ?L | EUR 1018 |
|
Description: Luciferase control virus of AAV serotype 6. |
|||
 A2LD1 3'UTR Luciferase Stable Cell Line |
|||
| TU000004 | ABM | 1.0 ml | EUR 1394 |
 A2ld1 3'UTR Luciferase Stable Cell Line |
|||
| TU101049 | ABM | 1.0 ml | Ask for price |
 A2ld1 3'UTR GFP Stable Cell Line |
|||
| TU151049 | ABM | 1.0 ml | Ask for price |
A2ld1 3'UTR Luciferase Stable Cell Line |
|||
| TU200006 | ABM | 1.0 ml | Ask for price |
A2ld1 3'UTR GFP Stable Cell Line |
|||
| TU250006 | ABM | 1.0 ml | Ask for price |
 A2LD1 3'UTR GFP Stable Cell Line |
|||
| TU050004 | ABM | 1.0 ml | EUR 1394 |
 Lenti-hTERT Antisense virus |
|||
| G201 | ABM | 10 ml | EUR 735 |
 Lenti-hTERT-Neo Virus |
|||
| G204 | ABM | 10 ml | EUR 811 |
 Lenti-Myc T58A Virus |
|||
| G217 | ABM | 10 ml | EUR 811 |
 Lenti-p53 siRNA Virus |
|||
| G219 | ABM | 10 ml | EUR 811 |
 Lenti-Ras V12 Virus |
|||
| G221 | ABM | 10 ml | EUR 811 |
 Lenti-Rb siRNA Virus |
|||
| G223 | ABM | 10 ml | EUR 811 |
 A2ld1/ Rat A2ld1 ELISA Kit |
|||
| ELI-24687r | Lifescience Market | 96 Tests | EUR 886 |
) Mouse Actc Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10010VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10012VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10013VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse SM22a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10014VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10015VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10016VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human CD11b Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10017VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10018VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1001VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse CD44 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10020VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human BM88 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10021VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10022VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10023VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Rat NSE Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10024VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse MBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10026VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Opsin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10027VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Insulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10028VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human LCK Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10032VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Rat Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10034VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10035VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse ALBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10036VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human NGN3 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10037VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10039VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1003VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10040VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human MAP2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10047VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human FABP7 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10048VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human ACTC Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10049VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1004VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10050VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human GFAP Differentiation Reporter (pRedZeo, Virus) |
|||
| SR10051VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1005VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human NKX2.5 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10067VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse CD8 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1006VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse CD68 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1008VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human CD2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1009VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Oct4 CR4-pGreenFire Response Reporter (virus) |
|||
| SR20070-VA-1 | SBI | >2 x 10^6 IFUs | EUR 735 |
) Steady-Luc Firefly HTS Assay Kit (10x100 ml) |
|||
| 30028-3 | Biotium | 1KIT | EUR 3145 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
|||
 A2LD1 Antibody |
|||
| 39425-100ul | SAB | 100ul | EUR 390 |
A2LD1 Antibody |
|||
| 39426-100ul | SAB | 100ul | EUR 390 |
 NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line |
|||
| TR860A-1 | SBI | >2 x 10^6 cells | EUR 3263 |
 Lenti-EF1α-hTERT Virus |
|||
| G706 | ABM | 10 ml | EUR 912 |
 Lenti-Bmi1 Virus, High Titer |
|||
| LV608 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-CDK4 Virus, High Titer |
|||
| LV609 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-hTERT Virus, High Titer |
|||
| LV615 | ABM | 5 x 20 ul | EUR 1521 |
) Human MLC-2v Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10011VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
 Puro) Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro |
|||
| SR10015VA-P | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10019VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10025VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human SPP-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1002VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10038VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
 Differentiation Reporter (pGreenZeo, Virus)) Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10041VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1007VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
 Anti-A2LD1 antibody |
|||
| PAab00013 | Lifescience Market | 100 ug | EUR 386 |
 A2LD1 cloning plasmid |
|||
| CSB-CL883610HU-10ug | Cusabio | 10ug | EUR 238 |
|
Description: A cloning plasmid for the A2LD1 gene. |
|||
 anti- A2LD1 antibody |
|||
| FNab00013 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against A2LD1 |
|||
 Lenti-HPV-16 E6/E7 Virus |
|||
| G268 | ABM | 10 ml | EUR 735 |
 Lenti-Myc T58A Virus, High Titer |
|||
| LV618 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-p53 siRNA Virus, High Titer |
|||
| LV619 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-Ras V12 Virus, High Titer |
|||
| LV620 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-Rb siRNA Virus, High Titer |
|||
| LV621 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-hTERT-Neo Virus, High Titer |
|||
| LV622 | ABM | 5 x 20 ul | EUR 1521 |
 Lenti-EF1α-hTERT-Hygro Virus |
|||
| LV631 | ABM | 10 ml | EUR 1059 |
) Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10070VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
 Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus |
|||
| SR20071-VA-1 | SBI | >2 x 10^6 IFUs | EUR 735 |
 pMIR-Reporter-RASA1(3 |
|||
| PVTB00444-2a | Lifescience Market | 2 ug | EUR 356 |
 pMIR-Reporter-IL13(3 |
|||
| PVTB00445-2a | Lifescience Market | 2 ug | EUR 356 |
 Lenti-CMV-hTERT-RFP-2A-Puro Virus |
|||
| LV625 | ABM | 10 ml | EUR 1059 |
 Lenti-EF1α-hTERT Virus, High Titer |
|||
| LV616 | ABM | 5 x 20 ul | EUR 1724 |
 Lenti-CMV-hTERT-GFP-2A-Puro Virus |
|||
| LV623 | ABM | 10 ml | EUR 1059 |
) Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10068VA-1 | SBI | >2 x 10^6 IFUs | EUR 755 |
) A2LD1 protein (His tag) |
|||
| 80R-1717 | Fitzgerald | 50 ug | EUR 397 |
|
Description: Purified recombinant Human A2LD1 protein |
|||
 A2LD1 ELISA KIT|Human |
|||
| EF007512 | Lifescience Market | 96 Tests | EUR 689 |
) A2LD1 Recombinant Protein (Human) |
|||
| RP000007 | ABM | 100 ug | Ask for price |
) A2LD1 Recombinant Protein (Mouse) |
|||
| RP112952 | ABM | 100 ug | Ask for price |
) A2LD1 Recombinant Protein (Rat) |
|||
| RP188432 | ABM | 100 ug | Ask for price |
 (Target 3)) A2ld1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4697504 | ABM | 1.0 ug DNA | EUR 154 |
 (Target 3)) A2ld1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7213404 | ABM | 1.0 ug DNA | EUR 154 |
 (Target 3)) A2LD1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0013604 | ABM | 1.0 ug DNA | EUR 154 |
 pGL3 3'UTR reporter WT 1.3 kb CD274 Hs 3'UTR Final Plasmid |
|||
| PVT17094 | Lifescience Market | 2 ug | EUR 325 |
 Lenti-HPV-16 E6/E7 Virus, High Titer |
|||
| LV617 | ABM | 5 x 20 ul | EUR 1420 |
 pLL-CMV-GFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL100VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-GFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL105VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-RFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL110VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-RFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL115VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-BFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL120VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-BFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL125VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-Luciferase-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL150VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-GFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL200VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-GFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL205VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-RFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL210VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-RFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL215VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-BFP-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL220VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-BFP-T2A-Blast [Lenti-LabelerTM virus] |
|||
| LL225VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-EF1a-Luciferase-T2A-Puro [Lenti-LabelerTM virus] |
|||
| LL250VA-1 | SBI | >2x10^6 IFUs | EUR 675 |
 pLL-CMV-rFLuc-T2A-GFP [Lenti-LabelerTM virus] |
|||
| LL300VA-1 | SBI | >2x10^6 IFUs | EUR 697 |
 Lentiviral Dual Reporter: CMV-GFP-T2A-Luciferase pre-packaged virus |
|||
| BLIV101VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
 Lentiviral Triple Reporter: CMV-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV102VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
 Lentiviral Dual Reporter: UBC-RFP-T2A-Luciferase pre-packaged virus |
|||
| BLIV200VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
 Lentiviral Triple Reporter: UBC-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV202VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
 Lentiviral Triple Reporter: MSCV-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV302VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
 BLIV 2.0 Reporter: CMV-Luciferase-EF1a-copGFP Pre-packaged Virus |
|||
| BLIV511VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
, EF1-Neo Marker) Human MLC-2v Differentiation Reporter (pGreenZeo, Virus), EF1-Neo Marker |
|||
| SR10011VA-N | SBI | >2 x 10^6 IFUs | EUR 755 |
 (pORF)) A2ld1 ORF Vector (Rat) (pORF) |
|||
| ORF062812 | ABM | 1.0 ug DNA | EUR 506 |
 (pORF)) A2LD1 ORF Vector (Human) (pORF) |
|||
| ORF000003 | ABM | 1.0 ug DNA | EUR 95 |
 (pORF)) A2ld1 ORF Vector (Mouse) (pORF) |
|||
| ORF037652 | ABM | 1.0 ug DNA | EUR 506 |
 SKOV-3/Luc Cell Line |
|||
| AKR-232 | Cell Biolabs | 1 vial | EUR 572 |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
 pT7- Luc |
|||
| PVT10670 | Lifescience Market | 2 ug | EUR 301 |
 pSBE- Luc |
|||
| PVT10816 | Lifescience Market | 2 ug | EUR 301 |
 pTRE3G- LUC |
|||
| PVT10818 | Lifescience Market | 2 ug | EUR 301 |
 pAP1- Luc |
|||
| PVT10819 | Lifescience Market | 2 ug | EUR 301 |
 pHSE- Luc |
|||
| PVT10820 | Lifescience Market | 2 ug | EUR 266 |
 pGRE- luc |
|||
| PVT10821 | Lifescience Market | 2 ug | EUR 266 |
 pCRE- Luc |
|||
| PVT10825 | Lifescience Market | 2 ug | EUR 301 |
 pViperin- Luc |
|||
| PVT10826 | Lifescience Market | 2 ug | EUR 301 |
 pTA- Luc |
|||
| PVT10827 | Lifescience Market | 2 ug | EUR 301 |
 pTAL- Luc |
|||
| PVT10829 | Lifescience Market | 2 ug | EUR 301 |
 pIRF3- Luc |
|||
| PVT10830 | Lifescience Market | 2 ug | EUR 301 |
 p53- Luc |
|||
| PVT10836 | Lifescience Market | 2 ug | EUR 266 |
 pBV-Luc |
|||
| PVT12245 | Lifescience Market | 2 ug | EUR 703 |
 pMR-Luc |
|||
| PVT14074 | Lifescience Market | 2 ug | EUR 703 |
 2C::tdTomato Reporter |
|||
| PVT10473 | Lifescience Market | 2 ug | EUR 266 |
 pMIR- Reporter Plasmid |
|||
| PVT1324 | Lifescience Market | 2 ug | EUR 266 |
 Pooled Virus Library of all Lenti-miR microRNA Precursor Constructs [4 virus aliquots] |
|||
| PMIRHPLVA-1 | SBI | 4 virus aliquots | EUR 4979 |
) Sox2 SRR2-pGreenFire Response Reporter (pre-packaged virus, EF1-Puro marker) |
|||
| SR20071-VA-P | SBI | >2 x 10^6 IFUs | EUR 735 |
 Lenti-CMV-hTERT-RFP-2A-Puro Virus, High Titer |
|||
| LV626 | ABM | 5 x 20 ul | EUR 1826 |
 Lenti-CMV-hTERT-GFP-2A-Puro Virus, High Titer |
|||
| LV624 | ABM | 5 x 20 ul | EUR 1826 |
 Lenti-EF1?¡À-hTERT-Hygro Virus, High Titer |
|||
| LV632 | ABM | 5 x 20 ul | EUR 1826 |
 lentiviral particles) β-Lactamase (Luciferase) lentiviral particles |
|||
| LVP335-luc | GenTarget | 1x107 IFU/ml x 200ul | EUR 349 |
|
Description: pre-made lentiviral particles expressing β-Lactamase gene. A firefly luciferase marker was expressed under RSV promoter. Particles is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
|||
 stable cell line) A549 / Luciferase (Puromycin) stable cell line |
|||
| SC043-Luc | GenTarget | 2 x 106 cell/ml x 1ml | EUR 920 |
|
Description: Luciferase (firefry) expression stable cell line in A549 human cancer cell line with Puromycin marker. |
|||
 Human AsPC1 / Luciferase Cell Line |
|||
| SC062-Luc | GenTarget | 2 x 106 cell/ml x 1ml | EUR 1500 |
|
Description: Firefly luciferase expression stable cell line in Human AsPC1 cells with Puromycin resistance |
|||
 mouse MOPC315 / Luciferase Cell Line |
|||
| SC063-Luc | GenTarget | 2 x 106 cell/ml x 1ml | EUR 2225 |
|
Description: Firefly luciferase expression stable cell line in mouse MOPC315 cells with Puromycin resistance |
|||
 Huamn SW403 / Luciferase Stable Cells |
|||
| SC067-Luc | GenTarget | 2 x 106 cell/ml x 1ml | EUR 1500 |
|
Description: Firefly luciferase expression stable cell line in human SW403 cells with Puromycin resistance |
|||
 Cell Line) Human PANC-1 / Luciferase (Puro) Cell Line |
|||
| SC068-Luc | GenTarget | 2 x 106 cell/ml x 1ml | EUR 2225 |
|
Description: Firefly luciferase expression stable cell line in Human PANC-1 cells with Puromycin resistance |
|||
 Human Gamma- glutamylaminecyclotransferase, A2LD1 ELISA KIT |
|||
| ELI-24712h | Lifescience Market | 96 Tests | EUR 824 |
 Mouse Gamma- glutamylaminecyclotransferase, A2ld1 ELISA KIT |
|||
| ELI-24713m | Lifescience Market | 96 Tests | EUR 865 |
) A2ld1 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4697501 | ABM | 3 x 1.0 ug | EUR 339 |
 Bovine Gamma- glutamylaminecyclotransferase, A2LD1 ELISA KIT |
|||
| ELI-49723b | Lifescience Market | 96 Tests | EUR 928 |
) A2ld1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7213401 | ABM | 3 x 1.0 ug | EUR 339 |
) A2LD1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0013601 | ABM | 3 x 1.0 ug | EUR 339 |
 Protein) Virus Parainfluenza Virus 3 (HPIV-3) Protein |
|||
| abx670267-1ml | Abbexa | 1 ml | EUR 592 |
 BLIV 2.0 Reporter: MSCV-Luciferase-EF1a-copGFP-T2A-Puro Pre-packaged Virus |
|||
| BLIV713VA-1 | SBI | >2 x10^6 IFUs | EUR 803 |
) pGreenFire 2.0 NFAT reporter virus (pGF2-NFAT-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR451VA-P | SBI | >2 x 10^6 IFUs | EUR 767 |
 pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro [Lenti-LabelerTM virus] |
|||
| LL310VA-1 | SBI | >2x10^6 IFUs | EUR 697 |
 pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro [Lenti-LabelerTM virus] |
|||
| LL320VA-1 | SBI | >2x10^6 IFUs | EUR 697 |
 pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro [Lenti-LabelerTM virus] |
|||
| LL410VA-1 | SBI | >2x10^6 IFUs | EUR 697 |
 pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro [Lenti-LabelerTM virus] |
|||
| LL420VA-1 | SBI | >2x10^6 IFUs | EUR 697 |
 Luciferase Reporter Assay Kit |
|||
| 55R-1540 | Fitzgerald | 200 assays | EUR 245 |
|
Description: Assay Kit for detection of Luciferase Reporter in the research laboratory |
|||
Luciferase Reporter Assay Kit |
|||
| K801-200 | Biovision | EUR 196 | |
 TFEB promoter-luciferase reporter |
|||
| PVT18227 | Lifescience Market | 2 ug | EUR 300 |
Luciferase Reporter Assay Kit |
|||
| K2181-200 | ApexBio | 200 assays | EUR 181 |
 IgK- IFN- luc |
|||
| PVT10425 | Lifescience Market | 2 ug | EUR 266 |
 pNFAT- TA- Luc |
|||
| PVT10808 | Lifescience Market | 2 ug | EUR 266 |
 pE2F- TA- Luc |
|||
| PVT10809 | Lifescience Market | 2 ug | EUR 266 |
 pISRE- TA- Luc |
|||
| PVT10810 | Lifescience Market | 2 ug | EUR 266 |
 pGAS- TA- Luc |
|||
| PVT10811 | Lifescience Market | 2 ug | EUR 266 |
 pP53- TA- luc |
|||
| PVT10814 | Lifescience Market | 2 ug | EUR 301 |
 pStat3- TA- luc |
|||
| PVT10815 | Lifescience Market | 2 ug | EUR 301 |
- Luc) pHes1 (2.5k)- Luc |
|||
| PVT10832 | Lifescience Market | 2 ug | EUR 266 |
- luc) pHes1 (467)- luc |
|||
| PVT10833 | Lifescience Market | 2 ug | EUR 266 |
 pNF-kB-Luc |
|||
| PVT1322 | Lifescience Market | 2 ug | EUR 325 |
 pGL3-ELAM-Luc |
|||
| PVT14533 | Lifescience Market | 2 ug | EUR 599 |
 proE-cad178-Luc |
|||
| PVT14614 | Lifescience Market | 2 ug | EUR 599 |
 pSynSRE-T-Luc |
|||
| PVT14626 | Lifescience Market | 2 ug | EUR 703 |
 pUC57-Tac-Luc |
|||
| PVT18215 | Lifescience Market | 2 ug | EUR 258 |
 p21-Luc Plasmid |
|||
| PVTB00035-2c | Lifescience Market | 2 ug | EUR 356 |
Fire-resistant CMV infection and CMV viral load at different levels associated with an increased risk of CMVP, CMVG, and CMVR. Compared with patients without CMV disease, significantly higher non-relapse mortality at 1 year after transplantation was observed in patients with CMVP and CMVR not CMVG. Patients with CMVP, In-CMVD, and CMVE have an overall mortality rate higher after diagnosis than patients with CMVG and CMVR (61.7%, 57.1%, 40.0% vs 27.7%, 18.6% , P = 0.001). In conclusion, time of onset, the viral dynamics, and different mortality between different CMV disease. CMV disease mortality remains high, especially for the CMVP, In-CMVD, and CMVE.